138 related articles for article (PubMed ID: 36996926)
1. Impact of age and gender on glioblastoma onset, progression, and management.
Colopi A; Fuda S; Santi S; Onorato A; Cesarini V; Salvati M; Balistreri CR; Dolci S; Guida E
Mech Ageing Dev; 2023 Apr; 211():111801. PubMed ID: 36996926
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive prognostic signature for glioblastoma patients based on transcriptomics and single cell sequencing.
Fan F; Zhang H; Dai Z; Zhang Y; Xia Z; Cao H; Yang K; Hu S; Guo Y; Ding F; Cheng Q; Zhang N
Cell Oncol (Dordr); 2021 Aug; 44(4):917-935. PubMed ID: 34142341
[TBL] [Abstract][Full Text] [Related]
3. The post-surgical era of GBM: How molecular biology has impacted on our clinical management. A review.
Monticelli M; Zeppa P; Zenga F; Altieri R; Mammi M; Bertero L; Castellano I; Cassoni P; Melcarne A; La Rocca G; Sabatino G; Ducati A; Garbossa D
Clin Neurol Neurosurg; 2018 Jul; 170():120-126. PubMed ID: 29777944
[TBL] [Abstract][Full Text] [Related]
4. EGFR amplification is a real independent prognostic impact factor between young adults and adults over 45yo with wild-type glioblastoma?
Armocida D; Pesce A; Frati A; Santoro A; Salvati M
J Neurooncol; 2020 Jan; 146(2):275-284. PubMed ID: 31889239
[TBL] [Abstract][Full Text] [Related]
5. A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999.
Chakrabarti I; Cockburn M; Cozen W; Wang YP; Preston-Martin S
Cancer; 2005 Dec; 104(12):2798-806. PubMed ID: 16288487
[TBL] [Abstract][Full Text] [Related]
6. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
[TBL] [Abstract][Full Text] [Related]
7. Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages.
Li G; Zhai Y; Wang Z; Wang Z; Huang R; Jiang H; Li R; Feng Y; Chang Y; Jiang T; Zhang W
Cancer Med; 2020 Mar; 9(6):1955-1965. PubMed ID: 31851783
[TBL] [Abstract][Full Text] [Related]
8. The influence of patient sex on clinical approaches to malignant glioma.
Matteoni S; Abbruzzese C; Villani V; Malorni W; Pace A; Matarrese P; Paggi MG
Cancer Lett; 2020 Jan; 468():41-47. PubMed ID: 31605777
[TBL] [Abstract][Full Text] [Related]
9. Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.
Umphlett M; Shea S; Tome-Garcia J; Zhang Y; Hormigo A; Fowkes M; Tsankova NM; Yong RL
BMC Cancer; 2020 Jan; 20(1):47. PubMed ID: 31959133
[TBL] [Abstract][Full Text] [Related]
10. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.
Polivka J; Polivka J; Rohan V; Pesta M; Repik T; Pitule P; Topolcan O
Biomed Res Int; 2014; 2014():735659. PubMed ID: 24511544
[TBL] [Abstract][Full Text] [Related]
11. The Multifaceted Glioblastoma: From Genomic Alterations to Metabolic Adaptations.
Quinones A; Le A
Adv Exp Med Biol; 2021; 1311():59-76. PubMed ID: 34014534
[TBL] [Abstract][Full Text] [Related]
12. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
[TBL] [Abstract][Full Text] [Related]
13. Epidemiologic and molecular prognostic review of glioblastoma.
Thakkar JP; Dolecek TA; Horbinski C; Ostrom QT; Lightner DD; Barnholtz-Sloan JS; Villano JL
Cancer Epidemiol Biomarkers Prev; 2014 Oct; 23(10):1985-96. PubMed ID: 25053711
[TBL] [Abstract][Full Text] [Related]
14. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
15. Sex Differences in Glioblastoma Immunotherapy Response.
Lee J; Kay K; Troike K; Ahluwalia MS; Lathia JD
Neuromolecular Med; 2022 Mar; 24(1):50-55. PubMed ID: 33864598
[TBL] [Abstract][Full Text] [Related]
16. Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration.
Ruano Y; Ribalta T; de Lope AR; Campos-Martín Y; Fiaño C; Pérez-Magán E; Hernández-Moneo JL; Mollejo M; Meléndez B
Am J Clin Pathol; 2009 Feb; 131(2):257-63. PubMed ID: 19141386
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
18. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
Hegi ME; Janzer RC; Lambiv WL; Gorlia T; Kouwenhoven MC; Hartmann C; von Deimling A; Martinet D; Besuchet Schmutz N; Diserens AC; Hamou MF; Bady P; Weller M; van den Bent MJ; Mason WP; Mirimanoff RO; Stupp R; Mokhtari K; Wesseling P; ;
Acta Neuropathol; 2012 Jun; 123(6):841-52. PubMed ID: 22249618
[TBL] [Abstract][Full Text] [Related]
19. Establishment and validation of an immune-based prognostic score model in glioblastoma.
Qin Z; Zhang X; Chen Z; Liu N
Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
[TBL] [Abstract][Full Text] [Related]
20. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
Batista R; Cruvinel-Carloni A; Vinagre J; Peixoto J; Catarino TA; Campanella NC; Menezes W; Becker AP; de Almeida GC; Matsushita MM; Clara C; Neder L; Viana-Pereira M; Honavar M; Castro L; Lopes JM; Carvalho B; Vaz RM; Máximo V; Soares P; Sobrinho-Simões M; Reis RM; Lima J
Int J Cancer; 2016 Jul; 139(2):414-23. PubMed ID: 26914704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
